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Abstract 25 
Introduction 26 
There is an unmet need for novel blood based biomarkers that offer timely and accurate 27 
diagnostic and prognostic testing in Inflammatory Bowel Diseases (IBD). We aimed to 28 
investigate the diagnostic and prognostic utility of serum calprotectin (SC) in IBD. 29 
Methods 30 
A total of 171 patients (n=96 IBD, n=75 non-IBD) were prospectively recruited. A multi-31 
biomarker model was derived using multivariable logistic regression analysis. Cox 32 
proportional hazards model was derived to assess the contribution of each variable to disease 33 
outcomes. 34 
Results 35 
SC correlated strongly with current biomarkers including faecal calprotectin (FC) (n=50, rho 36 
= 0.50, p=1.6x10
-4
). SC was the strongest individual predictor of IBD diagnosis (odds ratio 37 
(OR): 9.37(95%CI: 2.82-34.68), p=4.00×10
-4
) compared with other markers (CRP: OR 38 
8.52(95%CI: 2.75-28.63), p=2.80×10-4); albumin: OR 6.12(95%CI: 1.82-22.16), p=0.004). In 39 
a subset of 50 patients with paired SC and FC, the area under receiver operating characteristic 40 
discriminating IBD from controls was better for FC than SC (0.99, (95% CI 0.87-1.00) and 41 
0.87 (95% CI:0.78-0.97) respectively; p=0.01). 42 
At follow up (median 342 days; IQR: 88-563), SC predicted treatment escalation and/or 43 
surgery in IBD (HR 2.7, 95% CI: 1.1-4.9), in particular CD (HR 4.2, 95% CI 1.2-15.3). 44 
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A model incorporating SC and either CRP or albumin has a positive likelihood ratio of 24.14 45 
for IBD. At 1 year, our prognostic model can predict treatment escalation in IBD in 65% of 46 
cases (95% CI: 43-79%) and 80% (95% CI: 31-94%) in CD if 2 or more blood marker 47 
criteria are met. 48 
Conclusions 49 
A diagnostic and prognostic model that combines SC and other blood-based biomarkers 50 
accurately predicts the inflammatory burden in IBD and has the potential to predict disease 51 
and its outcomes. Our data warrants further detailed exploration and validation in large multi-52 
centre cohorts.  53 
 54 
 55 
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 68 
 69 
 70 
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Introduction 71 
 Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis 72 
(UC), are chronic, debilitating inflammatory disorders of the gastrointestinal tract affecting 73 
adults and children (1,2). A recent systematic review showed rising trends in the incidence 74 
and prevalence of IBD worldwide(3) associated with significant healthcare costs amounting 75 
to around £470 million in the UK, up to €5.6 billion annually in Europe and over $6 billion 76 
annually in the USA (3–8). With an ever expanding therapeutic repertoire, it is important to 77 
select patients who may benefit from early use of immunosuppressants’ and/or biological 78 
therapies in order to minimise irreversible luminal damage and prevent long-term 79 
complications.  80 
Blood-based biomarkers provide a non-invasive estimation of the inflammatory burden in 81 
newly diagnosed IBD. However relatively few blood-based biomarkers have been 82 
extensively validated in IBD, and fewer still are in routine use in the clinic (9). There is an 83 
emerging interest in discovering novel markers using multi-omic platforms that may be 84 
valuable in a variety of clinical settings including IBD diagnostics, disease activity 85 
assessments, predicting disease outcomes and response to therapy (9–11).  86 
The S100 family of proteins including S100A8/A9 (calprotectin) and S100A12 (calgranulin) 87 
have been implicated in disease pathogenesis and investigated as potential markers of 88 
inflammation(12,13). In IBD, faecal calprotectin (FC) has emerged as a particularly 89 
informative tool(14).  A recent meta-analysis of 13 studies and 1041 patients found that FC 90 
had a pooled sensitivity and specificity of 0.93 (0.85-0.97) and 0.96 (0.79-0.99) respectively 91 
for IBD and identified those individuals requiring endoscopy for suspected IBD(13). There 92 
are also data on the role of FC in other clinical settings, such as predicting post-operative CD 93 
recurrence and predicting outcomes in acute severe colitis(15,16). However, there are 94 
limitations to FC testing in clinical practice. Faecal collection can be a hurdle for patients(17) 95 
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and sample delivery and processing delays can hinder its clinical utility. In active UC, FC 96 
shows high within-day variability and the optimal timing for sampling is not clear(18,19). A 97 
blood based biomarker such as serum calprotectin (SC) may be more convenient in routine 98 
practice and more acceptable to patients. SC has been studied in diseases such as 99 
inflammatory arthropathies and cystic fibrosis (20–24). In Rheumatoid arthritis, SC was 100 
independently predictive of a 10 year radiographic disease progression (25), while in cystic 101 
fibrosis, SC predicted exacerbation and lung function decline(20,21).  102 
More recently, SC has been investigated in IBD to predict response to- and relapse following 103 
anti-tumour necrosis factor (anti-TNF) therapy(17,26). In CD patients, SC has a similar 104 
profile to high sensitivity C-reactive protein (hsCRP) and compliments FC and hsCRP for 105 
prediction of relapse after anti-TNF withdrawal (p=0.0173, 0.0024 and 0.0002; HR: 3.191, 106 
3.561 and 4.120 respectively) (17). In murine models, TNBS induced colitis is associated 107 
with higher SC levels that correlate closely to macroscopic and microscopic disease 108 
scores(27). We are yet to understand fully the relationship between SC and the other 109 
currently available biomarkers in IBD and the diagnostic and prognostic value of SC in IBD. 110 
Our study aims to investigate the role of SC in this clinical setting. 111 
Methods 112 
Study Design  113 
A prospective, single centre case control study was performed in patients with suspected or 114 
confirmed IBD at their first presentation to a tertiary gastrointestinal clinic. Data were 115 
collected for patient demographics including age, sex, age at diagnosis and date of diagnosis 116 
(Table 1). Details of drug therapy and concomitant medications were recorded. Laboratory 117 
markers including C-reactive protein (CRP) and albumin were measured as part of the 118 
research protocol while other routine markers including haemoglobin, white cell count, 119 
platelets and faecal calprotectin were recorded within 30 days from recruitment. 120 
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Inclusion criteria 121 
Patients with a new diagnosis of IBD were included in the study. The Lennard-Jones, 122 
Montreal  and Paris criteria were used for diagnosis and classification of clinical 123 
phenotypes(28–30). The control cohort consisted of healthy lab volunteers (HC) and patients 124 
with gastrointestinal symptoms (symptomatic controls) who had no discernible inflammatory 125 
disease, and a diagnosis of functional bowel disease at follow up.  126 
Sample collection and processing 127 
For SC analysis, blood samples were collected prospectively and serum was processed within 128 
2 hours of sampling (using centrifugation at 2500G for 15 min) and subsequently stored at 129 
−80°C until further use. Samples were analysed in duplicate using the CalproTM AS 130 
calprotectin ELISA (Calpro AS, Norway) according to manufacturer's instructions. Samples 131 
with a calprotectin result of >2500 ng/ml were diluted and retested. Coefficients of variation 132 
of <10% were included in the analysis.  133 
Ethics Statement 134 
The NHS Lothian SAHSC Bioresource granted approval for this study (reference number 135 
SR558) with all patients giving written and informed consent (15/ES/0094).  136 
Clinical Course in IBD 137 
Case note review was performed for all IBD cases. Treatment escalation was defined as the 138 
need for escalation and establishment of 2 or more immunomodulatory therapies and/or 139 
surgery for disease flare after initial induction of disease remission (criteria previously used 140 
by Lee et al)(31). In UC, the definition of treatment escalation also included any patient with 141 
a new diagnosis, requiring emergency colectomy during their index admission. 142 
Statistical analysis 143 
Data were analysed using Microsoft Excel 2010 (Microsoft, Redmond, WA, USA) and R 144 
3.2.2 (R Foundation for Statistical Computing, Vienna, Austria). Continuous data are 145 
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presented as medians and interquartile ranges and were analysed using a Mann–Whitney U-146 
test. Categorical data are presented as numbers and percentages, and were analysed using 147 
Fisher’s exact tests. Spearman’s rank-order correlation test was applied for correlations 148 
between variables. To determine the accuracy of blood parameter measurements as a 149 
prognostic test capable of diagnosing IBD, receiver operating characteristic (ROC) analyses 150 
were performed by plotting sensitivity against specificity using the ‘pROC’ package in R(32).  151 
Building diagnostic and prognostic models 152 
After univariable analyses, the most significant laboratory parameters (CRP, albumin and 153 
serum calprotectin) were included in multivariable models for IBD diagnosis and prognosis. 154 
CRP and serum calprotectin were log transformed to more closely approximate a normal 155 
distribution for further multivariable analysis. ROC analyses were used to define the optimal 156 
cut-points (highest sum of sensitivity + specificity) for both models. The optimal models 157 
were then selected by performing backward stepwise regression using the smallest Akaike 158 
information criterion (AIC) values and adjusted for treatment exposure. 159 
For the diagnostic model, an integer score was attributed to each variable according to its 160 
relative contribution in the model (as determined by the coefficients) and positive and 161 
negative predictive values were then calculated for each total score.   162 
For the prognostic model, a Cox proportional hazards model was derived to assess the 163 
contribution of each variable to disease outcomes. Thresholds were then identified using 164 
ROC analyses to allow stratification of patients to either a benign or an aggressive disease 165 
course (requiring treatment escalation and/or surgery), and to allow creation of survival 166 
curves.  167 
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Results 168 
Comparison of Serum Calprotectin with conventional biomarkers 169 
Overall, serum calprotectin was analysed in 171 patient serum samples from August 2013 to 170 
April 2015. Serum calprotectin correlated positively with CRP (rho=0.61, p=6.9x10
-19
) and 171 
negatively with albumin (rho= - 0.54, p=3.3x10-14). Paired full blood count was available 172 
within 30 days (median 0 days; range: -26 to 16 days) of recruitment in 147 patients.  Serum 173 
calprotectin correlated positively with Neutrophil count (rho=0.65, p=1.9x10-20) and 174 
negatively with Haemoglobin (rho= - 0.42, p=6.1 x10-8).  Paired FC was available within 30 175 
days (median 0 days, IQR: -5 to 5 days) of SC in 50 patients (IBD n=31, non-IBD n=19). 176 
Serum calprotectin correlated significantly with faecal calprotectin (Spearman’s rho = 0.50, 177 
p=1.6x10-4). Table 1 summarises the correlation of blood and faecal parameters.  SC 178 
demonstrated a stronger correlation with white cell count (William’s test, p=0.02) and 179 
neutrophils (p=0.03) in controls compared to IBD cases.  180 
Diagnostic utility of Serum Calprotectin in IBD 181 
In a subset of 156 patients (83 IBD and 73 non-IBD), blood sampling was performed within 182 
90 days from diagnosis (median 0 days; IQR 0-6). There were 35 patients with a diagnosis of 183 
CD, 45 patients with UC and 3 patients with IBDU in the IBD group. In CD, 44% had L3 +/- 184 
L4 disease and 62% had B1 behaviour according to the Montreal classification (33). In UC, 185 
33% had pancolitis (E4) and 11% had limited proctitis (E1) as per the Paris classification 186 
(30). Table 2 and Table 3 summarise the demographics and blood and faecal parameters for 187 
the IBD and control cohorts.  SC was significantly increased in IBD compared with controls 188 
(1010 ng/ml [IQR 796-1426ng/ml] vs 506ng/ml [IQR 362-725ng/ml], p=3.7 x 10-15) (Figure 189 
1). CRP and albumin were also significantly different between IBD and controls (CRP 190 
p=8.9x10
-15
; albumin p=4.9x10
-14
). There was no difference in SC between CD and UC 191 
(1015 ng/ml [IQR 740-1518 ng/ml] vs 911µg/g [IQR 809-1413ng/ml], p=0.79) and within 192 
controls (HC: 432 ng/ml [IQR 359-586] vs symptomatic controls: 563ng/ml [IQR 382-787]; 193 
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p=0.12). SC was not significantly associated with sex (p=0.14), age (rho -0.06, p=0.43) or 194 
smoking status (p=0.49). Serum calprotectin and CRP were able to discriminate IBD from 195 
controls with similar areas under the receiver operator characteristics curve (AUROC) of 0.87 196 
(95% confidence interval [CI] 0.82-0.93) and 0.86 (95% CI 0.80-0.91) respectively (Figure 2) 197 
(p=0.64 DeLong’s test for comparison of ROC curves). In those with paired SC and FC 198 
within 30 days, the AUROC for discriminating cases and controls was superior for FC (0.99, 199 
95% CI 0.98-1.00) than SC (0.87, 95% CI 0.78-0.97) (p=0.01 De Long’s test), as shown in 200 
Figure 2.  201 
Multivariable analysis 202 
Multivariable logistic regression analysis of predictors of IBD was performed on 155 cases 203 
(83 IBD, 72 non-IBD) where the data for the predictors were complete. Albumin, male 204 
gender, log transformed CRP and log transformed SC were significant predictors of IBD. 205 
Table 4 summarises the statistical significance of each covariate.   206 
Building an IBD Diagnosis Score 207 
Using the multivariable model, continuous variables were categorised using integer cut-208 
points guided by the ROC curves and observed relationship with diagnosis. The final scoring 209 
system for the diagnosis of IBD included SC>852ng/ml, Albumin<38g/L, CRP≥3.5mg/L and 210 
male gender. To formulate a numerical risk score, each variable was given a score based on 211 
the odds ratio generated from the linear model. Table 5 summarises the positive and negative 212 
predictive values for each score. Using this model, a SC> 852ng/ml and either a 213 
CRP≥3.5mg/L or albumin <38g/L has a sensitivity of 67%, specificity of 97% and a positive 214 
likelihood ratio (LR) of 24.14 for IBD. 215 
Predicting disease extent in IBD 216 
SC, CRP and albumin were not able to differentiate between IBD subtypes (CRP p=0.45; 217 
albumin p=0.67; SC p=0.49). Within the UC cohort, SC was significantly higher in those 218 
Page 9 of 73
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
American Journal of Gastroenterology
For Peer Review
10 
 
with disease beyond the rectum (> E1) compared to proctitis alone (E1) (median SC 219 
1078ng/ml IQR 820-1418 vs 812ng/ml IQR 698-821, p=0.03). Albumin also predicted 220 
disease extent in UC (p=0.01) but not CRP (p=0.05). In CD however, there was no significant 221 
difference in SC, CRP or albumin by disease location (p=0.47, 0.55 and 0.20 respectively).  222 
Predicting Disease outcomes in IBD 223 
Kaplan-Meier analyses were performed on a total of 83 patients with IBD. There were 35 224 
patients with a diagnosis of CD, 45 patients with UC and 3 patients with IBDU. The median 225 
age was 31 years (IQR: 26-41) and 69% were male (n=58). A total of 1(33%), 16 (46%), 226 
23(51%) patients required treatment escalation in the IBDU, CD and UC group respectively. 227 
Using backwards stepwise selection, albumin<37 g/L and SC ≥1046 ng/ml remained 228 
significant predictors of treatment escalation in IBD (logrank test p=5.1×10
-5
). Both 229 
biomarkers had similar hazards ratio (HR) as shown in Table 6a. A score was generated using 230 
both biomarkers at these thresholds. At a year, the estimated chance of treatment escalation 231 
was 21% (95% CI: 1-37%) if none of the criteria were met, 40% (95% CI: 17-56%) for 232 
patients meeting one criterion and 65% (95% CI: 43-78%) for those meeting both criteria 233 
(Figure 3a). 234 
In order to assess whether the time lag between diagnosis and blood sampling had an impact 235 
on the final model, stepwise regression analyses was performed for samples within 60 days 236 
(n=74) and 30 days (n=60) from diagnosis. SC remained a significant predictor of disease 237 
outcomes at 60 days and 30 days (p=0.003 and p=0.004 respectively).   238 
In 28 patients, paired FC was available within 30 days from diagnosis. Using a multivariate 239 
model which included age, gender, CRP, albumin, FC and SC, backward stepwise regression 240 
analysis was performed and only SC remained as a significant predictor (p=0.0004). FC did 241 
not predict disease outcomes in this cohort (p=0.85, HR=1.0). 242 
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 Further regression analyses were performed within the subgroups UC (Table 6b) and CD 243 
(Table 6c). In CD, CRP>24mg/L and SC>991ng/ml and albumin<26g/L predicted treatment 244 
escalation (logrank test p=0.003). At 1 year, the estimated chance of treatment escalation was 245 
11% (95%CI: 0-29%) for patients meeting none of the criteria, 30% (95% CI: 0-51%) for 246 
patients meeting one criterion and 80% (95% CI: 31-94%) for patients meeting two or more 247 
criteria (Figure 3b). 248 
 In UC, albumin< 37g/L and CRP>2.5g/L predicted a more aggressive disease course 249 
(logrank test p=0.001). At 1 year, the estimated chance of treatment escalation was 0 for 250 
patients meeting none of the criteria, 38% (95% CI: 0-61%) for patients meeting one criterion 251 
and 68% (95% CI: 41-83%) for patients meeting two criteria (Figure 3c). 252 
Discussion 253 
There is an unmet need for accurate diagnostic and prognostic biomarkers in IBD as currently 254 
available blood biomarkers lack sensitivity and/or specificity. Our study is the first to 255 
investigate the role of SC in patients with a new diagnosis of IBD. SC independently predicts 256 
a diagnosis of IBD with an OR of 9.37 (95%CI: 2.82-34.68). A combined blood-based 257 
biomarker diagnostic model including SC and either CRP or albumin has a high positive LR 258 
for IBD (positive LR 24.14). Similarly, SC can predict treatment escalation and/or surgery in 259 
IBD (HR 2.7, 95%CI: 1.1-4.9), in particular CD (HR 4.2, 95% CI 1.2-15.3).   260 
Calprotectin, a member of the S100 proteins, represents 45% of all cytosolic proteins in 261 
neutrophils compared to 1% in monocytes (34,35). Given the short half-life of SC (5 hours), 262 
it may provide a more dynamic test of the current inflammatory status compared with 263 
conventional inflammatory markers (half-life of CRP 18 hours, albumin 19 days) (36). SC 264 
correlates better with neutrophil count in controls compared to IBD patients; in IBD, SC 265 
levels may reflect calprotectin release from activated neutrophils and other immune cells such 266 
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as monocytes, macrophages and epithelial cells (Figure 4). SC shows a strong correlation 267 
with other markers such as CRP (r=0.61, p=6.9x10-19) similar to published studies (r=0.33-268 
0.59)(17,25,37,38) and a moderate correlation between SC and FC (0.50, p=1.6x10-4). 269 
As a diagnostic blood based marker, SC is the strongest predictor of IBD 9.37 (95%CI: 2.82-270 
34.68). In a clinical setting, blood markers such as CRP are often available, therefore 271 
investigating the utility of a combined marker may be more relevant as this allows for greater 272 
specificity in diagnostics (39,40).We generated an IBD scoring system that would allow 273 
clinicians to predict IBD in patients at their index clinical visit. If 2 blood marker criteria are 274 
met (score of 8 or above), there is a high likelihood of IBD (positive LR 24.14).  275 
 FC has a high NPV but a low PPV for IBD vs functional disease (cut off 50 µg/g, NPV 93% 276 
PPV 37%)(41). In practice, a blood biomarker model can complement the existing FC 277 
screening of patients with gastrointestinal symptoms in primary care. In the current climate of 278 
optimal tertiary care resource management, this model can be utilised for patients being 279 
referred for suspected IBD and help select and prioritise investigations for individuals with a 280 
high IBD score and a high likelihood of disease. The AUC for FC is superior to SC in our 281 
study (0.87 and 0.99 respectively, p=0.01). FC has an established role in IBD diagnostics, 282 
however in clinical practice faecal sampling and testing can be challenging. One 283 
consideration in interpreting these data is the lag between SC and FC testing. The median 284 
time lag between SC and FC testing was 0 days (IQR -5 to 5 days), but there were individuals 285 
with upto 30 days between SC and FC testing. Nonetheless, any time lag represents real life 286 
experience with faecal testing as often FC is not available until a few weeks after the clinic 287 
visit. There is a large variability in the concentration of FC in stool within a single day and 288 
storage conditions can impact on FC levels(18). Sampling faeces can be a hurdle for patients 289 
and individuals can either decline FC testing, fail to provide a sample or provide insufficient 290 
sample for analysis. These factors impact on the practical utility of FC. SC testing has the 291 
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potential to provide a more timely assessment of inflammation on the day of the visit. The 292 
cost per sample for performing SC testing are comparable to FC (£5; $7.3 equivalent). In 293 
addition, other costs related to sample handling and processing are likely to be lower as 294 
serum testing is often automated.  295 
Beyond diagnostics, studies have investigated the utility of non-invasive markers in 296 
predicting endoscopic activity. A recent meta-analyses evaluated the diagnostic accuracy of 297 
CRP, FC and stool lactoferrin (SL) for the assessment of endoscopically defined activity in 298 
IBD. The pooled AUC for CRP, FC and SL were 0.49(95% CI: 0.34-0.64), 0.88(CI: 0.84-299 
0.90) and 0.73(CI: 0.66-0.79)(42). There was however heterogeneity in the endoscopic index 300 
used. Other factors such as inclusion criteria, in particular time lag between blood/faecal 301 
sampling and endoscopy (0-7 days) differed(43–46). There is a need for future prospective 302 
studies investigating the performance of non-invasive endoscopic activity markers such as 303 
SC. 304 
In our study, SC predicts treatment escalation and/or surgery in IBD (HR 2.7, 95%CI: 1.1-305 
4.9), in particular CD (HR 4.2, 95% CI 1.2-15.3). We also generate blood-based prognostic 306 
models incorporating CRP, albumin and SC. At 1 year, our model can predict treatment 307 
escalation in IBD in 65% of cases (95% CI: 43-79%) and 80% (95% CI: 31-94%) in CD if 2 308 
or more criteria are met. Predicting the disease course early in individuals is becoming 309 
increasingly important in order to identify patients who would benefit from more aggressive 310 
therapy. In clinical practice, there is an unmet need for early indicators of persistent activity, 311 
either in a continuous or a relapsing-remitting manner despite initial induction therapy(31). 312 
These patients will often go on to require further immunomodulators, biological therapies 313 
and/or surgery. As quiescent IBD do not require such treatment escalations, we used the 314 
requirement of such treatment escalations to define an aggressive disease course (31). 315 
Clinical predictors have been studied previously. In CD, Beaugerie et al identified age, the 316 
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presence of perianal disease and requirement for steroids at diagnosis as independent 317 
predictive factors for a disabling course(47). However, biological markers were not analysed 318 
in that study.  Since then, the role of biomarkers in predicting the disease course has been the 319 
focus of many studies, although their effectiveness in predicting outcomes vary(31,48–51). 320 
Most studies suggest that CRP predicts relapse in IBD(48–50), although one study found it 321 
had no predictive value (52). There are several reasons for this observed variation and 322 
includes differences in defining an aggressive disease course, disease heterogeneity and 323 
disease duration prior to analyses. It is also possible that variations in CRP genotype may 324 
explain variations in its performance in adult cohort studies. This has been described in the 325 
paediatric population(53), but yet to be explored in adults. The role of FC in predicting 326 
colectomy in acute severe colitis (ASUC) has been investigated previously (AUC 0.65, 327 
p=0.04) and more recently, SC has been shown to predict colectomy in ASUC with an AUC 328 
of 0.69 (95%CI 0.53-0.81) compared to FC (AUC 0.58; 95%CI 0.35-0.81) and CRP (AUC 329 
0.71; 95%CI: 0.56-0.86) (16,38). SC has also been studied as a prognostic marker in 330 
predicting relapse after anti-TNF withdrawal and complements FC (>250µg/g) and 331 
hsCRP(>5mg/L) (p=0.0173, 0.0024 and 0.0002; HR: 3.191, 3.561 and 4.120 respectively) 332 
(17). Our study however is the first to explore the prognostic utility of SC at diagnosis. Future 333 
studies incorporating periodic SC testing to predict disease course in IBD may be useful.  334 
Our study does have certain limitations. The results are from a single tertiary centre and 335 
based on a select cohort of newly diagnosed IBD patients. The relatively small numbers 336 
within the sub-type of IBD limits the power to dissect factors predicting phenotype and our 337 
diagnostic and prognostic models require further validation. There were more females with 338 
functional bowel disease in the control cohort and this alone may underly the observation that 339 
male gender is a risk factor for IBD in our study.  The major strengths of this study include a 340 
prospective design and a cohort of newly diagnosed IBD aiming for the first time to explore 341 
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the correlation of SC with current biomarkers and build diagnostic and prognostic models for 342 
potential clinical use in IBD. 343 
Conclusion 344 
SC shows promise as a blood based biomarker in diagnosing and predicting disease course in 345 
IBD. A diagnostic and prognostic model that combines SC and other blood-based biomarkers 346 
accurately predicts the inflammatory burden in IBD and has the potential to predict disease 347 
and its outcomes. Our findings warrant further exploration and validation within large 348 
multicentre cohorts.  349 
 350 
 351 
 352 
 353 
 354 
 355 
 356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
What is Current Knowledge 
• Serum calprotectin (SC) has been studied as a prognostic marker in predicting 
relapse after anti-TNF withdrawal and complements FC and hsCRP for the 
prediction of relapse. 
• SC can predict colectomy in acute severe colitis with an AUC of 0.69, 
comparable to CRP. 
• SC correlates with other inflammatory blood markers such as CRP 
• SC has been studied in diseases such as inflammatory arthropathies and cystic 
fibrosis and can predict disease progression. 
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 385 
 386 
What is New Here 
• Serum Calprotectin (SC) is a strong individual predictor of a diagnosis of IBD  
• SC correlates with faecal calprotectin (FC) and is useful in diagnosis 
• SC can predict treatment escalation and/or surgery in IBD, in particular CD 
• Blood based diagnostic and prognostic models can provide an accurate reflection 
of the inflammatory burden and have the potential to predict disease and its 
outcomes. 
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 528 
Figure Legends 529 
Figure 1: Serum Calprotectin levels in patients with Crohn’s disease (CD), Ulcerative colitis 530 
(UC), Inflammatory bowel disease unclassified (IBDU), symptomatic controls (non-IBD) and 531 
healthy controls (HC) 532 
Footnote: Boxplots represent median and inter-quartile ranges for serum calprotectin within 533 
each subcohort 534 
Figure 2: Receiver operating curve analysis (ROC) of serum calprotectin (SC) and other 535 
blood based markers in differentiating Inflammatory bowel diseases (IBD) from non-IBD and 536 
ROC analysis of SC and faecal calprotectin (FC) (within 30 days) in discriminating 537 
Inflammatory bowel diseases (IBD) from non-IBD. 538 
Footnote: WCC:white cell count; CRP:C-reactive protein; Hb:Haemoglobin 539 
Figure 3a: Kaplan Meier survival curves of disease course using blood biomarkers to predict 540 
outcomes in newly diagnosed Inflammatory Bowel Diseases (IBD). Single marker represents 541 
either or albumin<37 g/L or serum calprotectin ≥ 1046ng/ml. Dual markers represents a 542 
combination of both variables. 543 
Figure 3b: Kaplan Meier survival curves of disease course using blood biomarkers to predict 544 
outcomes in newly diagnosed Crohn’s disease (CD) 545 
Footnote: ‘1 marker’ represents either CRP>24mg/L or albumin<26 g/L or serum 546 
calprotectin >991 ng/ml. ‘2 or 3 marker’ represents a combination of any 2 or 3 of the above 547 
mentioned variables. 548 
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Figure 3c: Kaplan Meier survival curves of disease course using blood biomarkers to predict 549 
outcomes in newly diagnosed Ulcerative Colitis (UC) 550 
Footnote: Single marker represents either albumin<37 g/L or CRP >2.5mg/L. Dual markers 551 
represents all the categorical variables as a combined biomarker.  552 
Figure 4: Correlation between log transformed serum calprotectin and neutrophil count in 553 
Inflammatory Bowel Diseases (IBD) versus controls (Non-IBD). 554 
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Abstract 25 
Introduction 26 
There is an unmet need for novel blood based biomarkers that offer timely and accurate 27 
diagnostic and prognostic testing in Inflammatory Bowel Diseases (IBD). We aimed to 28 
investigate the diagnostic and prognostic utility of serum calprotectin (SC) in IBD. 29 
Methods 30 
A total of 171 patients (n=96 IBD, n=75 non-IBD) were prospectively recruited. A multi-31 
biomarker model was derived using multivariable logistic regression analysis. Cox 32 
proportional hazards model was derived to assess the contribution of each variable to disease 33 
outcomes. 34 
Results 35 
SC correlated strongly with current biomarkers including faecal calprotectin (FC) 36 
(n=50, rho = 0.50, p=1.6x10
-4
). SC was the strongest individual predictor of IBD 37 
diagnosis (odds ratio (OR): 9.37(2.82-34.68), p=4.00×10
-4
) compared with other markers 38 
(CRP: OR 8.52(95%CI: 2.75-28.63), p=2.80×10
-4
); albumin: OR 6.12(95%CI: 1.82-39 
22.16), p=0.004). In a subset of 50 patients with paired SC and FC, the area under 40 
receiver operating characteristic discriminating IBD from controls was better for FC 41 
than SC (0.99, (95% CI 0.87-1.00) and 0.87 (95% CI: 0.78-0.97) respectively; p=0.01). 42 
At follow up (median 342 days; IQR: 88-563), SC predicted treatment escalation and/or 43 
surgery in IBD (HR 2.7, 95% CI: 1.1-4.9), in particular CD (HR 4.2, 95% CI 1.2-15.3). 44 
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A model incorporating SC and either CRP or albumin has a positive likelihood ratio of 45 
24.14 for IBD. At 1 year, our prognostic model can predict treatment escalation in IBD in 46 
65% of cases (95% CI: 43-79%) and 80% (95% CI: 31-94%) in CD if 2 or more blood 47 
marker criteria are met. 48 
Conclusions 49 
A diagnostic and prognostic model that combines SC and other blood-based biomarkers 50 
accurately predicts the inflammatory burden in IBD and has the potential to predict 51 
disease and its outcomes. Our data warrants further detailed exploration and validation in 52 
large multi-centre cohorts.  53 
 54 
 55 
 56 
 57 
 58 
 59 
 60 
 61 
 62 
 63 
 64 
 65 
 66 
 67 
 68 
 69 
 70 
Page 27 of 73
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
American Journal of Gastroenterology
For Peer Review
4 
 
Introduction 71 
 Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis 72 
(UC), are chronic, debilitating inflammatory disorders of the gastrointestinal tract affecting 73 
adults and children (1,2). A recent systematic review showed rising trends in the incidence 74 
and prevalence of IBD worldwide(3) associated with significant healthcare costs amounting 75 
to around £470 million in the UK, up to €5.6 billion annually in Europe and over $6 billion 76 
annually in the USA (3–8). With an ever expanding therapeutic repertoire, it is important to 77 
select patients who may benefit from early use of immunosuppressants’ and/or biological 78 
therapies in order to minimise irreversible luminal damage and prevent long-term 79 
complications.  80 
Blood-based biomarkers provide a non-invasive estimation of the inflammatory burden in 81 
newly diagnosed IBD. However relatively few blood-based biomarkers have been 82 
extensively validated in IBD, and fewer still are in routine use in the clinic (9). There is an 83 
emerging interest in discovering novel markers using multi-omic platforms that may be 84 
valuable in a variety of clinical settings including IBD diagnostics, disease activity 85 
assessments, predicting disease outcomes and response to therapy (9–11).  86 
The S100 family of proteins including S100A8/A9 (calprotectin) and S100A12 (calgranulin) 87 
have been implicated in disease pathogenesis and investigated as potential markers of 88 
inflammation(12,13). In IBD, faecal calprotectin (FC) has emerged as a particularly 89 
informative tool(14).  A recent meta-analysis of 13 studies and 1041 patients found that FC 90 
had a pooled sensitivity and specificity of 0.93 (0.85-0.97) and 0.96 (0.79-0.99) respectively 91 
for IBD and identified those individuals requiring endoscopy for suspected IBD(13). There 92 
are also data on the role of FC in other clinical settings, such as predicting post-operative CD 93 
recurrence and predicting outcomes in acute severe colitis(15,16). However, there are 94 
limitations to FC testing in clinical practice. Faecal collection can be a hurdle for patients(17) 95 
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and sample delivery and processing delays can hinder its clinical utility. In active UC, FC 96 
shows high within-day variability and the optimal timing for sampling is not clear(18,19). A 97 
blood based biomarker such as serum calprotectin (SC) may be more convenient in routine 98 
practice and more acceptable to patients. SC has been studied in diseases such as 99 
inflammatory arthropathies and cystic fibrosis (20–24). In Rheumatoid arthritis, SC was 100 
independently predictive of a 10 year radiographic disease progression (25), while in cystic 101 
fibrosis, SC predicted exacerbation and lung function decline(20,21).  102 
More recently, SC has been investigated in IBD to predict response to- and relapse following 103 
anti-tumour necrosis factor (anti-TNF) therapy(17,26). In CD patients, SC has a similar 104 
profile to high sensitivity C-reactive protein (hsCRP) and compliments FC and hsCRP for 105 
prediction of relapse after anti-TNF withdrawal (p=0.0173, 0.0024 and 0.0002; HR: 3.191, 106 
3.561 and 4.120 respectively) (17). In murine models, TNBS induced colitis is associated 107 
with higher SC levels that correlate closely to macroscopic and microscopic disease 108 
scores(27). We are yet to understand fully the relationship between SC and the other 109 
currently available biomarkers in IBD and the diagnostic and prognostic value of SC in IBD. 110 
Our study aims to investigate the role of SC in this clinical setting. 111 
Methods 112 
Study Design  113 
A prospective, single centre case control study was performed in patients with suspected or 114 
confirmed IBD at their first presentation to a tertiary gastrointestinal clinic. Data were 115 
collected for patient demographics including age, sex, age at diagnosis and date of diagnosis 116 
(Table 1). Details of drug therapy and concomitant medications were recorded. Laboratory 117 
markers including C-reactive protein (CRP) and albumin were measured as part of the 118 
research protocol while other routine markers including haemoglobin, white cell count, 119 
platelets and faecal calprotectin were recorded within 30 days from recruitment. 120 
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Inclusion criteria 121 
Patients with a new diagnosis of IBD were included in the study. The Lennard-Jones, 122 
Montreal  and Paris criteria were used for diagnosis and classification of clinical 123 
phenotypes(28–30). The control cohort consisted of healthy lab volunteers (HC) and 124 
patients with gastrointestinal symptoms (symptomatic controls) who had no discernible 125 
inflammatory disease, and a diagnosis of functional bowel disease at follow up.  126 
Sample collection and processing 127 
For SC analysis, blood samples were collected prospectively and serum was processed within 128 
2 hours of sampling (using centrifugation at 2500G for 15 min) and subsequently stored at 129 
−80°C until further use. Samples were analysed in duplicate using the CalproTM AS 130 
calprotectin ELISA (Calpro AS, Norway) according to manufacturer's instructions. Samples 131 
with a calprotectin result of >2500 ng/ml were diluted and retested. Coefficients of variation 132 
of <10% were included in the analysis.  133 
Ethics Statement 134 
The NHS Lothian SAHSC Bioresource granted approval for this study (reference number 135 
SR558) with all patients giving written and informed consent (15/ES/0094).  136 
Clinical Course in IBD 137 
Case note review was performed for all IBD cases. Treatment escalation was defined as the 138 
need for escalation and establishment of 2 or more immunomodulatory therapies and/or 139 
surgery for disease flare after initial induction of disease remission (criteria previously used 140 
by Lee et al)(31). In UC, the definition of treatment escalation also included any patient with 141 
a new diagnosis, requiring emergency colectomy during their index admission. 142 
Statistical analysis 143 
Data were analysed using Microsoft Excel 2010 (Microsoft, Redmond, WA, USA) and R 144 
3.2.2 (R Foundation for Statistical Computing, Vienna, Austria). Continuous data are 145 
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presented as medians and interquartile ranges and were analysed using a Mann–Whitney U-146 
test. Categorical data are presented as numbers and percentages, and were analysed using 147 
Fisher’s exact tests. Spearman’s rank-order correlation test was applied for correlations 148 
between variables. To determine the accuracy of blood parameter measurements as a 149 
prognostic test capable of diagnosing IBD, receiver operating characteristic (ROC) analyses 150 
were performed by plotting sensitivity against specificity using the ‘pROC’ package in R(32).  151 
Building diagnostic and prognostic models 152 
After univariable analyses, the most significant laboratory parameters (CRP, albumin and 153 
serum calprotectin) were included in multivariable models for IBD diagnosis and prognosis. 154 
CRP and serum calprotectin were log transformed to more closely approximate a normal 155 
distribution for further multivariable analysis. ROC analyses were used to define the optimal 156 
cut-points (highest sum of sensitivity + specificity) for both models. The optimal models 157 
were then selected by performing backward stepwise regression using the smallest Akaike 158 
information criterion (AIC) values and adjusted for treatment exposure. 159 
For the diagnostic model, an integer score was attributed to each variable according to its 160 
relative contribution in the model (as determined by the coefficients) and positive and 161 
negative predictive values were then calculated for each total score.   162 
For the prognostic model, a Cox proportional hazards model was derived to assess the 163 
contribution of each variable to disease outcomes. Thresholds were then identified using 164 
ROC analyses to allow stratification of patients to either a benign or an aggressive disease 165 
course (requiring treatment escalation and/or surgery), and to allow creation of survival 166 
curves.  167 
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Results 168 
Comparison of Serum Calprotectin with conventional biomarkers 169 
Overall, serum calprotectin was analysed in 171 patient serum samples from August 2013 to 170 
April 2015. Serum calprotectin correlated positively with CRP (rho=0.61, p=6.9x10
-19
) 171 
and negatively with albumin (rho= - 0.54, p=3.3x10
-14
). Paired full blood count was 172 
available within 30 days (median 0 days; range: -26 to 16 days) of recruitment in 147 173 
patients.  Serum calprotectin correlated positively with Neutrophil count (rho=0.65, 174 
p=1.9x10
-20
) and negatively with Haemoglobin (rho= - 0.42, p=6.1 x10
-8
).  Paired FC was 175 
available within 30 days (median 0 days, IQR: -5 to 5 days) of SC in 50 patients (IBD 176 
n=31, non-IBD n=19). Serum calprotectin correlated significantly with faecal 177 
calprotectin (Spearman’s rho = 0.50, p=1.6x10
-4
). Table 1 summarises the correlation of 178 
blood and faecal parameters.  SC demonstrated a stronger correlation with white cell count 179 
(William’s test, p=0.02) and neutrophils (p=0.03) in controls compared to IBD cases.  180 
Diagnostic utility of Serum Calprotectin in IBD 181 
In a subset of 156 patients (83 IBD and 73 non-IBD), blood sampling was performed 182 
within 90 days from diagnosis (median 0 days; IQR 0-6). There were 35 patients with a 183 
diagnosis of CD, 45 patients with UC and 3 patients with IBDU in the IBD group. In CD, 184 
44% had L3 +/- L4 disease and 62% had B1 behaviour according to the Montreal 185 
classification (33). In UC, 33% had pancolitis (E4) and 11% had limited proctitis (E1) as per 186 
the Paris classification (30). Table 2 and Table 3 summarise the demographics and blood and 187 
faecal parameters for the IBD and control cohorts.  SC was significantly increased in IBD 188 
compared with controls (1010 ng/ml [IQR 796-1426ng/ml] vs 506ng/ml [IQR 362-189 
725ng/ml], p=3.7 x 10
-15
) (Figure 1). CRP and albumin were also significantly different 190 
between IBD and controls (CRP p=8.9x10
-15
; albumin p=4.9x10
-14
). There was no 191 
difference in SC between CD and UC (1015 ng/ml [IQR 740-1518 ng/ml] vs 911µg/g [IQR 192 
809-1413ng/ml], p=0.79) and within controls (HC: 432 ng/ml [IQR 359-586] vs 193 
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symptomatic controls: 563ng/ml [IQR 382-787]; p=0.12). SC was not significantly 194 
associated with sex (p=0.14), age (rho -0.06, p=0.43) or smoking status (p=0.49). Serum 195 
calprotectin and CRP were able to discriminate IBD from controls with similar areas under 196 
the receiver operator characteristics curve (AUROC) of 0.87 (95% confidence interval 197 
[CI] 0.82-0.93) and 0.86 (95% CI 0.80-0.91) respectively (Figure 2) (p=0.64 DeLong’s 198 
test for comparison of ROC curves). In those with paired SC and FC within 30 days, the 199 
AUROC for discriminating cases and controls was superior for FC (0.99, 95% CI 0.98-200 
1.00) than SC (0.87, 95% CI 0.78-0.97) (p=0.01 De Long’s test), as shown in Figure 2.  201 
Multivariable analysis 202 
Multivariable logistic regression analysis of predictors of IBD was performed on 155 cases 203 
(83 IBD, 72 non-IBD) where the data for the predictors were complete. Albumin, male 204 
gender, log transformed CRP and log transformed SC were significant predictors of IBD. 205 
Table 4 summarises the statistical significance of each covariate.   206 
Building an IBD Diagnosis Score 207 
Using the multivariable model, continuous variables were categorised using integer cut-208 
points guided by the ROC curves and observed relationship with diagnosis. The final scoring 209 
system for the diagnosis of IBD included SC>852ng/ml, Albumin<38g/L, CRP≥3.5mg/L and 210 
male gender. To formulate a numerical risk score, each variable was given a score based on 211 
the odds ratio generated from the linear model. Table 5 summarises the positive and negative 212 
predictive values for each score. Using this model, a SC> 852ng/ml and either a 213 
CRP≥3.5mg/L or albumin <38g/L has a sensitivity of 67%, specificity of 97% and a 214 
positive likelihood ratio (LR) of 24.14 for IBD. 215 
Predicting disease extent in IBD 216 
SC, CRP and albumin were not able to differentiate between IBD subtypes (CRP p=0.45; 217 
albumin p=0.67; SC p=0.49). Within the UC cohort, SC was significantly higher in those 218 
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with disease beyond the rectum (> E1) compared to proctitis alone (E1) (median SC 219 
1078ng/ml IQR 820-1418 vs 812ng/ml IQR 698-821, p=0.03). Albumin also predicted 220 
disease extent in UC (p=0.01) but not CRP (p=0.05). In CD however, there was no significant 221 
difference in SC, CRP or albumin by disease location (p=0.47, 0.55 and 0.20 respectively).  222 
Predicting Disease outcomes in IBD 223 
Kaplan-Meier analyses were performed on a total of 83 patients with IBD. There were 35 224 
patients with a diagnosis of CD, 45 patients with UC and 3 patients with IBDU. The median 225 
age was 31 years (IQR: 26-41) and 69% were male (n=58). A total of 1(33%), 16 (46%), 226 
23(51%) patients required treatment escalation in the IBDU, CD and UC group respectively. 227 
Using backwards stepwise selection, albumin<37 g/L and SC ≥1046 ng/ml remained 228 
significant predictors of treatment escalation in IBD (logrank test p=5.1×10
-5
). Both 229 
biomarkers had similar hazards ratio (HR) as shown in Table 6a. A score was generated 230 
using both biomarkers at these thresholds. At a year, the estimated chance of treatment 231 
escalation was 21% (95% CI: 1-37%) if none of the criteria were met, 40% (95% CI: 232 
17-56%) for patients meeting one criterion and 65% (95% CI: 43-78%) for those 233 
meeting both criteria (Figure 3a). 234 
In order to assess whether the time lag between diagnosis and blood sampling had an impact 235 
on the final model, stepwise regression analyses was performed for samples within 60 days 236 
(n=74) and 30 days (n=60) from diagnosis. SC remained a significant predictor of disease 237 
outcomes at 60 days and 30 days (p=0.003 and p=0.004 respectively).   238 
In 28 patients, paired FC was available within 30 days from diagnosis. Using a multivariate 239 
model which included age, gender, CRP, albumin, FC and SC, backward stepwise regression 240 
analysis was performed and only SC remained as a significant predictor (p=0.0004). FC did 241 
not predict disease outcomes in this cohort (p=0.85, HR=1.0). 242 
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 Further regression analyses were performed within the subgroups UC (Table 6b) and CD 243 
(Table 6c). In CD, CRP>24mg/L and SC>991ng/ml and albumin<26g/L predicted treatment 244 
escalation (logrank test p=0.003). At 1 year, the estimated chance of treatment escalation was 245 
11% (95%CI: 0-29%) for patients meeting none of the criteria, 30% (95% CI: 0-51%) for 246 
patients meeting one criterion and 80% (95% CI: 31-94%) for patients meeting two or more 247 
criteria (Figure 3b). 248 
 In UC, albumin< 37g/L and CRP>2.5g/L predicted a more aggressive disease course 249 
(logrank test p=0.001). At 1 year, the estimated chance of treatment escalation was 0 for 250 
patients meeting none of the criteria, 38% (95% CI: 0-61%) for patients meeting one criterion 251 
and 68% (95% CI: 41-83%) for patients meeting two criteria (Figure 3c). 252 
Discussion 253 
There is an unmet need for accurate diagnostic and prognostic biomarkers in IBD as currently 254 
available blood biomarkers lack sensitivity and/or specificity. Our study is the first to 255 
investigate the role of SC in patients with a new diagnosis of IBD. SC independently 256 
predicts a diagnosis of IBD with an OR of 9.37 (95%CI: 2.82-34.68). A combined blood-257 
based biomarker diagnostic model including SC and either CRP or albumin has a high 258 
positive LR for IBD (positive LR 24.14). Similarly, SC can predict treatment escalation 259 
and/or surgery in IBD (HR 2.7, 95%CI: 1.1-4.9), in particular CD (HR 4.2, 95% CI 1.2-260 
15.3).   261 
Calprotectin, a member of the S100 proteins, represents 45% of all cytosolic proteins in 262 
neutrophils compared to 1% in monocytes (34,35). Given the short half-life of SC (5 hours), 263 
it may provide a more dynamic test of the current inflammatory status compared with 264 
conventional inflammatory markers (half-life of CRP 18 hours, albumin 19 days) (36). SC 265 
correlates better with neutrophil count in controls compared to IBD patients; in IBD, SC 266 
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levels may reflect calprotectin release from activated neutrophils and other immune cells such 267 
as monocytes, macrophages and epithelial cells (Figure 4). SC shows a strong correlation 268 
with other markers such as CRP (r=0.61, p=6.9x10-19) similar to published studies (r=0.33-269 
0.59)(17,25,37,38) and a moderate correlation between SC and FC (0.50, p=1.6x10-4). 270 
As a diagnostic blood based marker, SC is the strongest predictor of IBD 9.37 (95%CI: 271 
2.82-34.68). In a clinical setting, blood markers such as CRP are often available, therefore 272 
investigating the utility of a combined marker may be more relevant as this allows for greater 273 
specificity in diagnostics (39,40).We generated an IBD scoring system that would allow 274 
clinicians to predict IBD in patients at their index clinical visit. If 2 blood marker criteria 275 
are met (score of 8 or above), there is a high likelihood of IBD (positive LR 24.14).  276 
 FC has a high NPV but a low PPV for IBD vs functional disease (cut off 50 µg/g, NPV 93% 277 
PPV 37%)(41). In practice, a blood biomarker model can complement the existing FC 278 
screening of patients with gastrointestinal symptoms in primary care. In the current climate of 279 
optimal tertiary care resource management, this model can be utilised for patients being 280 
referred for suspected IBD and help select and prioritise investigations for individuals with a 281 
high IBD score and a high likelihood of disease. The AUC for FC is superior to SC in our 282 
study (0.87 and 0.99 respectively, p=0.01). FC has an established role in IBD diagnostics, 283 
however in clinical practice faecal sampling and testing can be challenging. One 284 
consideration in interpreting these data is the lag between SC and FC testing. The median 285 
time lag between SC and FC testing was 0 days (IQR -5 to 5 days), but there were individuals 286 
with upto 30 days between SC and FC testing. Nonetheless, any time lag represents real life 287 
experience with faecal testing as often FC is not available until a few weeks after the clinic 288 
visit. There is a large variability in the concentration of FC in stool within a single day and 289 
storage conditions can impact on FC levels(18). Sampling faeces can be a hurdle for 290 
patients and individuals can either decline FC testing, fail to provide a sample or 291 
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provide insufficient sample for analysis. These factors impact on the practical utility of FC. 292 
SC testing has the potential to provide a more timely assessment of inflammation on the day 293 
of the visit. The cost per sample for performing SC testing are comparable to FC (£5; 294 
$7.3 equivalent). In addition, other costs related to sample handling and processing are 295 
likely to be lower as serum testing is often automated.  296 
Beyond diagnostics, studies have investigated the utility of non-invasive markers in 297 
predicting endoscopic activity. A recent meta-analyses evaluated the diagnostic 298 
accuracy of CRP, FC and stool lactoferrin (SL) for the assessment of endoscopically 299 
defined activity in IBD. The pooled AUC for CRP, FC and SL were 0.49(95% CI: 0.34-300 
0.64), 0.88(CI: 0.84-0.90) and 0.73(CI: 0.66-0.79)(42). There was however heterogeneity 301 
in the endoscopic index used. Other factors such as inclusion criteria, in particular time 302 
lag between blood/faecal sampling and endoscopy (0-7 days) differed(43–46). There is a 303 
need for future prospective studies investigating the performance of non-invasive 304 
endoscopic activity markers such as SC. 305 
In our study, SC predicts treatment escalation and/or surgery in IBD (HR 2.7, 95%CI: 306 
1.1-4.9), in particular CD (HR 4.2, 95% CI 1.2-15.3). We also generate blood-based 307 
prognostic models incorporating CRP, albumin and SC. At 1 year, our model can predict 308 
treatment escalation in IBD in 65% of cases (95% CI: 43-79%) and 80% (95% CI: 31-94%) 309 
in CD if 2 or more criteria are met. Predicting the disease course early in individuals is 310 
becoming increasingly important in order to identify patients who would benefit from more 311 
aggressive therapy. In clinical practice, there is an unmet need for early indicators of 312 
persistent activity, either in a continuous or a relapsing-remitting manner despite initial 313 
induction therapy(31). These patients will often go on to require further immunomodulators, 314 
biological therapies and/or surgery. As quiescent IBD do not require such treatment 315 
escalations, we used the requirement of such treatment escalations to define an aggressive 316 
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disease course (31). Clinical predictors have been studied previously. In CD, Beaugerie et al 317 
identified age, the presence of perianal disease and requirement for steroids at diagnosis as 318 
independent predictive factors for a disabling course(47). However, biological markers were 319 
not analysed in that study.  Since then, the role of biomarkers in predicting the disease course 320 
has been the focus of many studies, although their effectiveness in predicting outcomes 321 
vary(31,48–51). Most studies suggest that CRP predicts relapse in IBD(48–50), although one 322 
study found it had no predictive value (52). There are several reasons for this observed 323 
variation and includes differences in defining an aggressive disease course, disease 324 
heterogeneity and disease duration prior to analyses. It is also possible that variations in CRP 325 
genotype may explain variations in its performance in adult cohort studies. This has been 326 
described in the paediatric population(53), but yet to be explored in adults. The role of FC in 327 
predicting colectomy in acute severe colitis (ASUC) has been investigated previously (AUC 328 
0.65, p=0.04) and more recently, SC has been shown to predict colectomy in ASUC with an 329 
AUC of 0.69 (95%CI 0.53-0.81) compared to FC (AUC 0.58; 95%CI 0.35-0.81) and CRP 330 
(AUC 0.71; 95%CI: 0.56-0.86) (16,38). SC has also been studied as a prognostic marker in 331 
predicting relapse after anti-TNF withdrawal and complements FC (>250µg/g) and 332 
hsCRP(>5mg/L) (p=0.0173, 0.0024 and 0.0002; HR: 3.191, 3.561 and 4.120 respectively) 333 
(17). Our study however is the first to explore the prognostic utility of SC at diagnosis. 334 
Future studies incorporating periodic SC testing to predict disease course in IBD may 335 
be useful.  336 
Our study does have certain limitations. The results are from a single tertiary centre and 337 
based on a select cohort of newly diagnosed IBD patients. The relatively small numbers 338 
within the sub-type of IBD limits the power to dissect factors predicting phenotype and our 339 
diagnostic and prognostic models require further validation. There were more females with 340 
functional bowel disease in the control cohort and this alone may underly the 341 
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observation that male gender is a risk factor for IBD in our study.  The major strengths 342 
of this study include a prospective design and a cohort of newly diagnosed IBD aiming for 343 
the first time to explore the correlation of SC with current biomarkers and build diagnostic 344 
and prognostic models for potential clinical use in IBD. 345 
Conclusion 346 
SC shows promise as a blood based biomarker in diagnosing and predicting disease course in 347 
IBD. A diagnostic and prognostic model that combines SC and other blood-based biomarkers 348 
accurately predicts the inflammatory burden in IBD and has the potential to predict disease 349 
and its outcomes. Our findings warrant further exploration and validation within large 350 
multicentre cohorts.  351 
 352 
 353 
 354 
 355 
 356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
What is Cur ent Knowledge 
• Serum calprotectin (SC) has been studied as a prognostic marker in predicting 
relapse after anti-TNF withdrawal and complements FC and hsCRP for the 
prediction of relapse. 
• SC can predict colectomy in acute severe colitis with an AUC of 0.69, 
comparable to CRP. 
• SC correlates with other inflammatory blood markers such as CRP 
• SC has been studied in diseases such as inflammatory arthropathies and cystic 
fibrosis and can predict disease progression. 
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 385 
 386 
What is New Here 
• Serum Calprotectin (SC) is a strong individual predictor of a diagnosis of IBD  
• SC correlates with faecal calprotectin (FC) and is useful in diagnosis 
• SC can predict treatment escalation and/or surgery in IBD, in particular CD 
• Blood based diagnostic and prognostic models can provide an accurate reflection 
of the inflammatory burden and have the potential to predict disease and its 
outcomes. 
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 528 
Figure Legends 529 
Figure 1: Serum Calprotectin levels in patients with Crohn’s disease (CD), Ulcerative 530 
colitis (UC), Inflammatory bowel disease unclassified (IBDU), symptomatic controls 531 
(non-IBD) and healthy controls (HC) 532 
Footnote: Boxplots represent median and inter-quartile ranges for serum calprotectin 533 
within each subcohort 534 
Figure 2: Receiver operating curve analysis (ROC) of serum calprotectin (SC) and other 535 
blood based markers in differentiating Inflammatory bowel diseases (IBD) from non-IBD and 536 
ROC analysis of SC and faecal calprotectin (FC) (within 30 days) in discriminating 537 
Inflammatory bowel diseases (IBD) from non-IBD. 538 
Footnote: WCC:white cell count; CRP:C-reactive protein; Hb:Haemoglobin 539 
Figure 3a: Kaplan Meier survival curves of disease course using blood biomarkers to predict 540 
outcomes in newly diagnosed Inflammatory Bowel Diseases (IBD). Single marker represents 541 
either or albumin<37 g/L or serum calprotectin ≥ 1046ng/ml. Dual markers represents a 542 
combination of both variables. 543 
Figure 3b: Kaplan Meier survival curves of disease course using blood biomarkers to predict 544 
outcomes in newly diagnosed Crohn’s disease (CD) 545 
Footnote: ‘1 marker’ represents either CRP>24mg/L or albumin<26 g/L or serum 546 
calprotectin >991 ng/ml. ‘2 or 3 marker’ represents a combination of any 2 or 3 of the above 547 
mentioned variables. 548 
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Figure 3c: Kaplan Meier survival curves of disease course using blood biomarkers to predict 549 
outcomes in newly diagnosed Ulcerative Colitis (UC) 550 
Footnote: Single marker represents either albumin<37 g/L or CRP >2.5mg/L. Dual markers 551 
represents all the categorical variables as a combined biomarker.  552 
Figure 4: Correlation between log transformed serum calprotectin and neutrophil count in 553 
Inflammatory Bowel Diseases (IBD) versus controls (Non-IBD). 554 
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Table 1: Correlation coefficient (spearman rho) between Serum Calprotectin (SC) and blood 
and faecal parameters 
 
Abbreviations: SC: serum calprotectin, WCC: white cell count; Neut: neutrophil count; 
Lymp: lymphocyte count; Alb: albumin; Hb: haemoglobin; FC: faecal calprotectin; Plts: 
Platelet count 
 
 
Parameters Number of patients rho(spearman rho) P value 
SC – CRP 171 0.61 6.9x10
-19 
SC – WCC 147 0.61 3.8 x 10
-17 
SC – Neut 147 0.65 1.9x10
-20
 
SC – Lymp 147 -0.03 0.68 
SC – Alb 171 -0.54 3.3x10
-14 
SC-Hb 147 -0.42 6.1 x10
-8 
SC-Plts 147 0.49 1.3×10
-10 
SC-FC 50 0.50 1.6x10
-4 
Parameters IBD(n) rho(p-value) Non-
IBD(n) 
rho(p-value) 
SC – CRP 96 0.41(3.9x10
-5) 75 0.30(0.01) 
SC – WCC 92 0.37(2.3x10
-4
) 55 0.66(4.3x10
-8
) 
SC - Neut 92 0.43(2.2x10
-5
) 55 0.68(1.0x10
-8
) 
SC – Lymp 92 -0.18(0.08) 55 0.48(2.0x10
-4) 
SC – Alb 95 -0.39(6.9x10
-5
) 75 -0.09(0.46) 
SC-Hb 92 -0.41(4.7x10
-5) 55 -0.05(0.75) 
SC-Plts 92 0.31 (0.002) 55 0.27(0.04) 
SC-FC 31 -0.07(0.72) 19                      0.13(0.59) 
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Table 2: Study demographics, Montreal classification, disease behaviour for newly 
diagnosed Inflammatory Bowel Diseases (IBD) and control cohorts 
 
 
Variables Inflammatory Bowel 
Diseases (n=83) 
Controls 
(n=73) 
Subtype IBD(CD:UC:IBDU)  35:45:3  
Subtype control group(HC:IBS)   27:46 
Males (%) 58(69) 33(45) 
Smoking status (current: never: 
ex) 
14:41:26 12:36:15 
Median age (range) 31(18-73) 31(19-64) 
Montreal classification for CD  
L1 +/-L4 10 
L2 +/-L4 10 
L3 +/-L4 15 
Montreal behaviour for CD  
B1 21 
B2 2 
B3 6 
Not available 6 
Paris Extent for UC 
E1 5 
E2 14 
E3 10 
E4 15 
Not available 1  
 
Footnote: CD: Crohn’s disease; UC: ulcerative colitis; IBD-U: Inflammatory bowel disease 
unclassified; HC: healthy controls; SC: symptomatic controls.  
Smoking status was available in 81 patients with IBD and 63 patients with non-IBD. 
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Table 3: Blood and faecal parameters for Inflammatory Bowel Disease (IBD) and control 
cohorts 
 
 IBD Controls 
Test Number of 
patients 
Median (IQR) Number of 
patients 
Median (IQR) 
Haemoglobin (g/L) 79 128(119-139) 53 140(135-150) 
Neutrophil (10
9
/L) 79 5.8(3.9-7.5) 53 3.2(2.5-4.1) 
Lymphocyte (mg/L) 79 1.7(1.2-2.1) 53 1.8(1.5-2.2) 
White cell 
count(10
9
/L) 
79 8.3(6.5-10.7) 53 5.8(4.7-6.6) 
Platelet count (10
9
/L) 79 335(269-432) 53 244(209-277) 
C-reactive 
protein(mg/L) 
83 11(3.0-35.5) 73 1.0(0.5-2.0) 
Faecal calprotectin 
within 30 days (µg/g) 
31 770(660-880) 19 19(19-25) 
Albumin (g/L) 83 35(29.0-39.0) 73 42(39-46) 
Serum Calprotectin 
(ng/ml) 
83 1015(811-1442) 73 506(362-725) 
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Table 4: Multiple logistic regression of predictors of Inflammatory Bowel Diseases versus 
controls (n=155) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Continuous variable analysis 
Variable Odds ratio (95%CI) P value 
Log(C-reactive protein) 6.60 (2.18-23.67) 0.002 
Log(Serum Calprotectin) 296.85 (9.55-18512.49) 0.003 
Albumin 0.85 (0.75-0.94) 0.003 
Gender 4.00(1.22-14.68) 0.03 
Categorical variable analysis 
Categorical threshold Odds ratio (95%CI) P-value for 
thresholds 
C-reactive protein>3.5mg/L 8.52(2.75-28.63) 2.80×10
-4
 
Serum Calprotectin >852ng/ml 9.37(2.82-34.68) 4.00×10
-4 
Albumin<38g/L 6.12 (1.82-22.16) 0.004 
Male gender 2.87(0.97-9.24) 0.06 
Page 52 of 73
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
American Journal of Gastroenterology
For Peer Review
Table 5a: Sensitivity, specificity, positive and negative likelihood ratios (LR) of the 
Inflammatory Bowel Diseases (IBD) scoring parameters. Each variable score is based on the 
odds ratio generated from the linear model 
 
IBD Score Sensitivity Specificity Positive LR Negative LR 
1 or above 0.96 0.31 1.39 0.12 
3 or above 0.89 0.68 2.79 0.16 
4 or above 0.85 0.75 3.41 0.20 
5 or above 0.84 0.89 7.57 0.18 
6 or above 0.74 0.93 10.71 0.28 
7 or above 0.68 0.96 16.39 0.33 
8 or above 0.67 0.97 24.14 0.34 
 
Table 5b: Sensitivity, specificity, positive and negative likelihood ratios (LR) of the 
Inflammatory Bowel Diseases (IBD) of the individual markers. 
Test Sensitivity Specificity Positive LR Negative LR 
C-reactive 
protein>3.5mg/L 
0.70 0.86 5.03 0.35 
Albumin<38 g/L 0.66 0.88 5.30 0.39 
Serum 
Calprotectin>852ng/ml 
0.69 0.90 7.06 0.35 
 
 
Variable Score 
Serum Calprotectin>852ng/ml 5 
Albumin <38g/L 3 
CRP≥3.5mg/L 4 
Male gender 1 
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Table 6a: Multivariable analysis for predictive factors for an aggressive disease course in 
patients with Inflammatory Bowel Diseases (n=83): final Cox proportional hazards model 
 
 
 
Table 6b: Multivariable analysis for predictive factors for an aggressive disease course in 
patients with Ulcerative Colitis (n=45): final Cox proportional hazards model 
 
 
 
Table 6c: Multivariable analysis for predictive factors for an aggressive disease course in 
patients with Crohn’s disease (n=35): final Cox proportional hazards model 
 
Categorical variable analysis 
Categorical variable Categorical 
threshold 
Hazards ratio 
(95%CI) 
AIC P-value for 
thresholds 
Serum  
Calprotectin(SC) 
≥1046 ng/ml 2.7(1.3-5.6) 309.2 0.007 
Albumin <37 g/L 2.5(1.1-5.6) 306.5 0.03 
 Categorical variable analysis 
Categorical 
variable 
Categorical threshold Hazards ratio 
(95%CI) 
AIC P-value for 
thresholds 
Albumin <37 g/L 3.8(1.2-11.9) 148.0 0.02 
C-reactive 
protein(CRP) 
>2.5mg/L 2.6(0.7-9.6) 147.0 0.15 
Categorical variable analysis 
Categorical variable Categorical 
threshold 
Hazards ratio 
(95%CI) 
AIC P-value for 
thresholds 
C-reactive protein(CRP) >24mg/L 2.7(1.0-7.4) 93.3 0.06 
Albumin <26 g/L 2.6(0.8-9.1) 91.9 0.13 
Serum Calprotectin >991ng/ml 4.2(1.2-15.3) 95.1 0.03 
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Figure 1: Serum Calprotectin levels in patients with Crohn’s disease (CD), Ulcerative colitis (UC), 
Inflammatory bowel disease unclassified (IBDU), symptomatic controls (non-IBD) and healthy controls (HC) 
 
Footnote: Boxplots represent median and inter-quartile ranges for serum calprotectin within each subcohort 
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Figure 2: Receiver operating curve analysis (ROC) of serum calprotectin (SC) and other blood based markers 
in differentiating Inflammatory bowel diseases (IBD) from non-IBD and ROC analysis of SC and faecal 
calprotectin (FC) (within 30 days) in discriminating Inflammatory bowel diseases (IBD) from non-IBD.  
Footnote: WCC:white cell count; CRP:C-reactive protein; Hb:Haemoglobin  
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Figure 3a: Kaplan Meier survival curves of disease course using blood biomarkers to predict outcomes in 
newly diagnosed Inflammatory Bowel Diseases (IBD). Single marker represents either or albumin<37 g/L or 
serum calprotectin ≥ 1046ng/ml. Dual markers represents a combination of both variables.  
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Figure 3b: Kaplan Meier survival curves of disease course using blood biomarkers to predict outcomes in 
newly diagnosed Crohn’s disease (CD)  
Footnote: ‘1 marker’ represents either CRP>24mg/L or albumin<26 g/L or serum calprotectin >991 ng/ml. 
‘2 or 3 marker’ represents a combination of any 2 or 3 of th  above mentioned variables.  
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Figure 3c: Kaplan Meier survival curves of disease course using blood biomarkers to predict outcomes in 
newly diagnosed Ulcerative Colitis (UC)  
Footnote: Single marker represents either albumin<37 g/L or CRP >2.5mg/L. Dual markers represents all 
the categorical variables as a combined biomarker.  
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Figure 4: Correlation between log transformed serum calprotectin and neutrophil count in Inflammatory 
Bowel Diseases (IBD) versus controls (Non-IBD).  
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Supplementary Table 1: Disease outcomes in patients with Ulcerative colitis (UC) and Crohn’s disease (CD). 
Diagnosi
s 
Treatment 
Escalation? 
Age Sex 
Total follow 
up time 
(days) 
Diagnosis to SC 
sampling (days) 
SC sampling to 
Rx 
escalation(days
) 
Rx immediately prior 
escalation 
Treatment escalation 
UC Yes 46 M 126 1 30 Prednisolone Azathioprine and 2nd course of Prednisolone 
UC Yes 54 M 374 73 27 5ASA Azathioprine and Prednisolone 
UC Yes 35 F 547 -14 316 5ASA Azathioprine and Prednisolone 
UC Yes 33 F 609 18 67 5ASA Azathioprine and Prednisolone 
UC Yes 53 M 871 2 47 5ASA Azathioprine and Prednisolone 
UC Yes 20 M 893 -14 269 5ASA Azathioprine and Prednisolone 
UC Yes 29 M 201 0 44 Prednisolone 
Ciclosporin and Azathioprine during 2nd 
admission 
UC Yes 19 M 470 2 43 5ASA Ciclosporin, Prednisolone and Azathioprine 
UC Yes 31 M 781 -1 408 5ASA Ciclosporin, Prednisolone and Azathioprine 
UC Yes 34 M 498 37 225 Azathioprine Golilumab 
UC Yes 33 F 69 41 26 Azathioprine Infliximab 
UC Yes 26 F 549 8 44 Azathioprine Infliximab 
UC No 35 M 118 0 NA 5ASA No change in therapy 
UC No 38 F 132 43 NA 5ASA No change in therapy 
UC No 32 M 145 0 NA 5ASA No change in therapy 
UC No 32 M 145 0 NA 5ASA No change in therapy 
UC No 53 M 345 12 NA 5ASA No change in therapy 
UC No 40 M 367 24 NA 5ASA No change in therapy 
UC No 24 F 410 0 NA 5ASA No change in therapy 
UC No 27 F 456 57 NA 5ASA No change in therapy 
UC No 37 F 472 78 NA 5ASA No change in therapy 
UC No 48 M 484 68 NA 5ASA No change in therapy 
UC No 41 M 499 0 NA Azathioprine No change in therapy 
UC No 57 M 518 23 NA 5ASA No change in therapy 
UC No 27 M 575 -39 NA 5ASA No change in therapy 
UC No 24 F 578 0 NA 5ASA No change in therapy 
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UC No 58 M 604 75 NA 5ASA No change in therapy 
UC No 50 M 637 61 NA 5ASA No change in therapy 
UC No 62 M 657 32 NA 5ASA No change in therapy 
UC No 26 M 670 30 NA No medications No change in therapy 
UC No 57 F 788 45 NA 5ASA No change in therapy 
UC No 38 M 795 27 NA 5ASA No change in therapy 
UC No 52 M 801 78 NA 5ASA No change in therapy 
UC No 34 M 837 -1 NA Azathioprine No change in therapy 
UC Yes 29 M 366 0 7 IVMP and Ciclosporin Panproctocolectomy 
UC Yes 44 M 451 2 6 MP and Prednisolone Panproctocolectomy 
UC Yes 21 M 126 13 35 
Prednisolone and 
Ciclosporin 
Subtotal colectomy 
UC Yes 59 M 433 5 1 5ASA Subtotal colectomy 
UC Yes 43 F 602 25 323 MP  Subtotal colectomy 
UC Yes 22 M 643 22 303 5ASA Subtotal colectomy 
UC Yes 27 F 672 4 153 5ASA Subtotal colectomy 
UC Yes 22 M 712 0 23 5ASA Subtotal colectomy 
UC Yes 23 F 871 1 496 5ASA and Azathioprine Subtotal colectomy 
UC Yes 29 M 385 -12 12 
Prednisolone and 
Ciclosporin 
Subtotal colectomy 
UC Yes 39 M 342 0 161 MP Vedolizumab 
CD Yes 42 M 602 1 413 Azathioprine Adalimumab 
CD Yes 27 M 852 0 311 Azathioprine Adalimumab 
CD Yes 27 M 870 0 614 MP Adalimumab 
CD Yes 18 M 358 44 275 Infliximab Azathioprine 
CD Yes 24 F 510 0 47 Infliximab Azathioprine 
CD Yes 25 M 454 0 91 Prednisolone Azathioprine and 2
nd
 course Prednisolone 
CD Yes 19 M 525 35 27 Prednisolone Azathioprine and Infliximab 
CD Yes 23 M 504 34 69 5ASA Azathioprine and Prednisolone 
CD Yes 27 F 644 11 566 5ASA Azathioprine and Prednisolone 
CD Yes 27 F 762 50 84 MP and Infliximab Ileocaecal resection 
CD No 29 M 768 -2 6 IVMP Ileocaecal resection at index admission 
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CD Yes 32 M 618 30 161 MP Infliximab 
CD Yes 19 F 664 20 45 MP Infliximab 
CD Yes 33 F 718 1 42 Azathioprine Infliximab 
CD Yes 30 M 803 -27 64 Azathioprine Infliximab 
CD Yes 24 M 837 0 140 Azathioprine Infliximab 
CD No 41 M 150 -4 NA Azathioprine No change in therapy 
CD No 59 F 160 -2 NA Polymeric diet No change in therapy 
CD No 31 M 177 -113 NA No medications No change in therapy 
CD No 72 M 347 46 NA No medications No change in therapy 
CD No 29 M 408 52 NA No medications No change in therapy 
CD No 38 M 417 87 NA No medications No change in therapy 
CD No 29 M 506 -18 NA Azathioprine No change in therapy 
CD No 52 M 513 57 NA 5ASA No change in therapy 
CD No 31 M 555 0 NA Azathioprine No change in therapy 
CD No 29 F 582 -36 NA Azathioprine No change in therapy 
CD No 18 M 637 28 NA No medications No change in therapy 
CD No 57 F 719 33 NA 5ASA No change in therapy 
CD No 40 F 721 18 NA Azathioprine No change in therapy 
CD No 23 M 726 22 NA No medications No change in therapy 
CD No 19 M 781 -6 NA Azathioprine No change in therapy 
CD No 38 F 821 64 NA No medications No change in therapy 
CD No 36 F 914 76 NA 5ASA No change in therapy 
CD Yes 21 M 504 4 99 MP Subtotal colectomy 
CD Yes 22 F 319 -206 NA Azathioprine No change in therapy 
 
Footnote: F: Female; M: Male; NA: Not applicable; 5ASA: 5-aminosalicylates; MP: mercaptopurine; IVMP: Intravenous methylprednisolone 
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Supplementary Table 2a: Clinical symptoms (Simple Clinical Colitis Activity Index) at recruitment in patients with Ulcerative Colitis (UC) and Inflammatory 
Bowel Disease-Unclassified (IBDU) 
Diagnosis Rx naive 
General 
Well Being Complications 
SCCAI Day 
BO 
SCCAI Night 
BO 
SCCAI 
Urgency 
SCCAI Blood 
PR SCCAI Score 
UC Y 2 0 0 0 1 3 6 
UC N 1 1 0 0 1 2 5 
UC N 1 0 1 1 NA 3 NA 
UC Y 1 0 1 0 1 0 3 
UC Y 1 0 0 0 1 2 4 
UC N 0 1 0 0 0 0 1 
UC Y 1 0 0 0 0 2 3 
UC Y 1 0 2 1 1 3 8 
UC Y 1 0 2 1 0 2 6 
UC Y 2 0 3 1 1 3 10 
UC Y 3 1 1 1 1 2 9 
UC N 2 0 2 1 1 3 9 
UC N 0 0 0 0 1 3 4 
UC N 0 0 0 0 0 0 0 
UC N 0 0 1 0 1 2 4 
UC N 1 0 2 1 1 2 7 
UC N 1 0 0 0 0 2 3 
UC N 0 0 0 1 2 0 3 
UC Y 2 0 3 2 1 3 11 
UC Y 1 0 3 0 3 3 10 
UC N 1 0 1 0 1 3 6 
UC N 1 0 1 2 1 3 8 
UC Y 2 0 0 2 1 2 7 
UC Y 1 0 2 0 1 3 7 
UC N NA NA NA NA NA NA NA 
UC N 1 0 3 1 1 3 9 
UC Y 1 0 0 0 1 0 2 
UC N 1 0 3 2 1 3 10 
UC Y 1 0 0 0 1 2 4 
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UC N 2 0 0 1 1 2 6 
UC N 4 0 3 2 3 3 15 
UC Y 2 0 3 2 3 3 13 
UC Y 1 0 2 1 1 2 7 
UC Y 1 1 0 0 0 3 5 
UC N 0 0 0 0 1 3 4 
UC Y 2 0 NA NA 1 3 NA 
UC N 1 0 0 0 0 1 2 
UC Y 1 1 0 0 1 2 5 
UC Y 1 0 2 0 1 3 7 
UC Y 1 1 1 0 1 2 6 
UC N 1 1 0 0 1 2 5 
UC N 1 1 0 1 1 2 6 
UC N 1 0 0 0 2 3 6 
UC Y 3 0 1 1 1 2 8 
UC N 2 0 1 2 2 3 10 
IBDU Y 0 0 0 0 0 2 2 
IBDU N 1 0 1 0 1 0 3 
IBDU Y 2 0 1 1 2 3 9 
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Supplementary Table 2b: Clinical symptoms (Harvey Bradshaw Index) at recruitment in patients with Crohn’s Disease (CD) 
Diagnosis Rx naive Weight loss 
General 
Well Being 
Abdominal 
Pain BO per day 
Abdominal 
mass Complications HBI Score 
CD Y N 0 0 2 NA 0 NA 
CD N N NA 1 11 0 1 NA 
CD Y Y 1 0 1 0 1 3 
CD Y Y 1 0 1 0 0 2 
CD N Y 2 1 10 0 1 14 
CD Y N 1 3 9 0 0 13 
CD Y Y 2 2 5 1 0 10 
CD Y N 1 1 1 2 0 5 
CD Y Y 2 2 0 1 0 5 
CD Y Y 0 0 1 0 0 1 
CD Y Y 2 2 1 0 1 6 
CD Y Y 0 0 1 0 0 1 
CD N N 1 0 11 0 0 12 
CD Y Y NA 3 10 0 1 NA 
CD Y Y 1 1 2 0 0 4 
CD Y Y 1 0 1 0 1 3 
CD Y Y NA NA NA NA NA NA 
CD Y N 0 2 1 3 0 6 
CD N Y 1 1 2 0 1 5 
CD Y N 1 1 2 0 2 6 
CD Y Y 1 2 4 0 0 7 
CD N Y 1 3 2 0 2 8 
CD N Y 1 0 5 0 1 7 
CD Y Y 2 2 10 0 2 16 
CD Y Y 1 2 7 0 1 11 
CD Y Y 1 1 10 0 0 12 
CD Y Y 2 2 8 0 0 12 
CD Y N 2 0 5 0 1 8 
CD Y N 2 2 7 NA 2 NA 
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CD Y N 0 0 0 0 2 2 
CD Y NA NA 0 1 0 0 NA 
CD Y NA 1 3 3 0 2 9 
CD Y N 1 1 2 0 0 4 
CD Y N 0 0 4 0 0 4 
CD Y Y 1 3 2 0 0 6 
 
Footnote: Rx naïve: Treatment naïve status at sampling; SC: serum calprotectin; BO: Bowel habits; SCCAI: Simple clinical colitis activity index; HBI: Harvey 
Bradshaw Index; NA: Not available; Y: yes; N: No 
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Supplementary Table 3: Summary of investigations undertaken in the control cohort  
Diagnosis Age Sex 
Faecal Calprotectin 
(µg/g) Colonoscopy Radiology 
HC 47 M NA no no 
HC 
42 M NA no no 
HC 
32 M NA no no 
HC 
30 M NA no no 
HC 
31 F NA no no 
HC 
24 F NA no no 
HC 
33 M NA no no 
HC 
34 F NA no no 
HC 
32 F NA no no 
HC 
30 M NA no no 
HC 
32 F NA no no 
HC 
54 F NA no no 
HC 
39 M NA no no 
HC 
43 M NA no no 
HC 
59 F NA no no 
HC 
35 F NA no no 
HC 
25 F NA no no 
HC 
20 F NA no no 
HC 
31 M NA no no 
HC 
19 F NA no no 
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HC 
64 F NA no no 
HC 
49 F NA no no 
HC 
24 M NA no no 
HC 
30 M NA no no 
HC 
30 M NA no no 
HC 
33 M NA no no 
HC 
34 M NA no no 
Non-IBD 31 F 19 no no 
Non-IBD 22 M 19 yes no 
Non-IBD 33 F 19 no yes 
Non-IBD 21 M 19 yes yes 
Non-IBD 31 M 19 yes no 
Non-IBD 21 M 19 no no 
Non-IBD 29 F 19 yes no 
Non-IBD 37 F 19 yes no 
Non-IBD 28 M NA yes no 
Non-IBD 28 F NA yes no 
Non-IBD 33 F NA yes no 
Non-IBD 27 F 19 no no 
Non-IBD 23 F 30 yes yes 
Non-IBD 33 F 19 no no 
Non-IBD 29 F NA yes no 
Non-IBD 23 F 19 yes no 
Non-IBD 44 F NA yes no 
Non-IBD 41 M NA no yes 
Non-IBD 28 F 120 yes yes 
Non-IBD 26 F 19 yes yes 
Non-IBD 33 M 19 yes no 
Non-IBD 41 F 19 no no 
Non-IBD 19 F 19 yes yes 
Page 69 of 73
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
American Journal of Gastroenterology
For Peer Review
Non-IBD 22 F 19 yes yes 
Non-IBD 29 F 30 yes no 
Non-IBD 39 F 19 yes yes 
Non-IBD 34 F 210 yes yes 
Non-IBD 28 F 80 yes no 
Non-IBD 23 M 19 yes yes 
Non-IBD 29 F NA yes no 
Non-IBD 21 M 19 yes no 
Non-IBD 22 M 19 no no 
Non-IBD 44 M 470 yes yes 
Non-IBD 39 M 19 yes no 
Non-IBD 32 M NA yes no 
Non-IBD 30 F 160 yes no 
Non-IBD 37 F 190 yes no 
Non-IBD 36 M NA yes no 
Non-IBD 34 F 110 yes yes 
Non-IBD 43 M NA yes no 
Non-IBD 45 M NA yes no 
Non-IBD 23 M 19 no no 
Non-IBD 41 M NA yes yes 
Non-IBD 21 M 19 no no 
Non-IBD 20 F 19 yes no 
Non-IBD 20 F 19 yes no 
 
Footnote: HC: Healthy lab volunteers; Non-IBD: Symptomatic controls; M: Male; F: Female; NA: Not available 
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 Section & Topic No Item Reported on page # 
     
 TITLE OR ABSTRACT  Blood-based Diagnostic and Prognostic Models in IBD: The Utility of Serum Calprotectin  
 
1 
  1 Identification as a study of diagnostic accuracy using at least one measure of accuracy 
(such as sensitivity, specificity, predictive values, or AUC) 
6 and 7 
 ABSTRACT    
  2 Structured summary of study design, methods, results, and conclusions  
(for specific guidance, see STARD for Abstracts) 
2 and 3 
 INTRODUCTION    
  3 Scientific and clinical background, including the intended use and clinical role of the index test 4 and 5 
  4 Study objectives and hypotheses 4 and 5 
 METHODS    
 Study design 5 Whether data collection was planned before the index test and reference standard  
were performed (prospective study) or after (retrospective study) 
6 
 Participants 6 Eligibility criteria  6 
  7 On what basis potentially eligible participants were identified  
(such as symptoms, results from previous tests, inclusion in registry) 
6 
  8 Where and when potentially eligible participants were identified (setting, location and dates) 6 
  9 Whether participants formed a consecutive, random or convenience series 6 
 Test methods 10a Index test, in sufficient detail to allow replication 6 
  10b Reference standard, in sufficient detail to allow replication 6 
  11 Rationale for choosing the reference standard (if alternatives exist) 6 
  12a Definition of and rationale for test positivity cut-offs or result categories  
of the index test, distinguishing pr -specified from exploratory 
6 
  12b Definition of and rationale for test positivity cut-offs or result categories  
of the reference standard, distinguishing pre-specified from exploratory 
6 
  13a Whether clinical information and reference standard results were available  
to the performers/readers of the index test 
7 
  13b Whether clinical information and index test results were available  
to the assessors of the reference standard 
7 
 Analysis 14 Methods for estimating or comparing measures of diagnostic accuracy 7 
  15 How indeterminate index test or reference standard results were handled 7 
  16 How missing data on the index test and reference standard were handled 7 
  17 Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory 7 
  18 Intended sample size and how it was determined 7 
 RESULTS    
 Participants 19 Flow of participants, using a diagram NA 
  20 Baseline demographic and clinical characteristics of participants 8 
  21a Distribution of severity of disease in those with the target condition 8 
  21b Distribution of alternative diagnoses in those without the target condition 8 
  22 Time interval and any clinical interventions between index test and reference standard 10 
 Test results 23 Cross tabulation of the index test results (or their distribution)  
by the results of the reference standard 
8 
  24 Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals) 8 
  25 Any adverse events from performing the index test or the reference standard NA 
 DISCUSSION    
  26 Study limitations, including sources of potential bias, statistical uncertainty, and generalisability 13 
  27 Implications for practice, including the intended use and clinical role of the index test 13 
 OTHER 
INFORMATION 
   
  28 Registration number and name of registry 6 
  29 Where the full study protocol can be accessed NA 
  30 Sources of funding and other support; role of funders 15 
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STARD 2015 
AIM  
STARD stands for “Standards for Reporting Diagnostic accuracy studies”. This list of items was developed to contribute to the 
completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative 
study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts 
submitted for publication.  
EXPLANATION 
A diagnostic accuracy study evaluates the ability of one or more medical tests to correctly classify study participants as 
having a target condition. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition 
in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, 
a combination of these, or any other method for collecting information about the current health status of a patient. 
The test whose accuracy is evaluated is called index test. A study can evaluate the accuracy of one or more index tests. 
Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the 
index test results with those of the reference standard. The reference standard is the best available method for establishing 
the presence or absence of the target condition. An accuracy study can rely on one or more reference standards. 
If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the 
reference standard can be used to estimate the sensitivity of the index test (the proportion of participants with the target 
condition who have a positive index test), and its specificity (the proportion without the target condition who have a negative 
index test). From this cross tabulation (sometimes referred to as the contingency or “2x2” table), several other accuracy 
statistics can be estimated, such as the positive and negative predictive values of the test. Confidence intervals around 
estimates of accuracy can then be calculated to quantify the statistical precision of the measurements. 
If the index test results can take more than two values, categorization of test results as positive or negative requires a test 
positivity cut-off. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) 
curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The 
area under the ROC curve informs in a single numerical value about the overall diagnostic accuracy of the index test.  
The intended use of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The 
clinical role of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, 
replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.  
Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical 
tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was 
not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.  
DEVELOPMENT 
This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, 
researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would 
help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of 
conclusions and recommendations. The list represents an update of the first version, which was published in 2003.  
 
More information can be found on http://www.equator-network.org/reporting-guidelines/stard. 
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